Advertisement

AmBisome®: Long Circulating Liposomal Formulation of Amphotericin B

  • Jill P. Adler-Moore
  • Richard T. Proffitt
Part of the Biotechnology Intelligence Unit book series (BIOIU)

Abstract

AmBisome® is a newly commercialized formulation of amphotericin B incorporated into small unilamellar liposomes composed of cohesive bilayer forming lipids (see chapter 1). An important feature of this formulation is that the amphotericin B is stably incorporated into the liposome bilayer.1 In recent years, this and other lipid formulations have been devised to improve the utility of Fungizone, a micellar formulation of amphotericin B which rapidly disassociates upon iv administration. While the standard formulation is proven clinically, it is limited by severe renal toxicity, and many life-threatening fungal infections cannot successfully be treated.2,3 For the purposes of this chapter, Fungizone is considered “free” amphotericin B (ampB) administration.

Keywords

Visceral Leishmaniasis Kidney Tissue Aspergillus Fumigatus Antimicrobial Chemotherapy Liposomal Amphotericin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Adler-Moore J, Proffitt RT. Development, characterization, efficacy and mode of action of AmBisome,® a unilamellar liposomal formulation of amphotericin B. J Liposome Research 1993; 3(3)429–45o.Google Scholar
  2. 2.
    Utz JP. Amphotericin B toxicity: general side effects. Ann Int Med 1964; 61: 340–354.PubMedCrossRefGoogle Scholar
  3. 3.
    McCurdy KK, Frederic M, Elkinton JR. Renal tubular acidosis due to amphotericin B. N Eng J Med 1968; 278: 124–131.CrossRefGoogle Scholar
  4. 4.
    Proffitt RT, Adler-Moore J, Fujii G et al. Stability and mode of action of AmBisome (liposomal amphotericin B). J Controlled Release 1994; z8: 342–343.CrossRefGoogle Scholar
  5. 5.
    McAndrews BJ, Lee MJA, Adler-Moore JP. Comparative toxicities of fungizone and AmBisome for cultured kidney cells and macrophages. General Proceeding of the ASM Meeting for American Society for Microbiology. Atlanta, Georgia 1993:11 (Abstract).Google Scholar
  6. 6.
    Proffitt RT, Satorius A, Chiang S et al. Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents. J Antimicrobial Chemotherapy. 1991; 28 (Suppl. B): 49–61.CrossRefGoogle Scholar
  7. 7.
    Fielding RM, Singer AW, Wang LH et al. Relationship of pharmacokinetics and drug distribution in tissue to increased safety of amphotericin B colloidal dispersion in dogs. Antimicrobial Agents Chemotherapy 1992; 36: 299–307.CrossRefGoogle Scholar
  8. 8.
    Meunier F, Prentice HG, Ringden O. Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial. J Antimicrobial Chemotherapy 1991; 28 (suppl B): 83–91.CrossRefGoogle Scholar
  9. 9.
    Ringden O, Andstrom E, Remberger M et al. Safety of liposomal amphotericin B (AmBisome) in 187 transplant recipients treated with cyclosporin. Bone Marrow Transplantation 1994; 14 (Supp1.5): S10 - S14.PubMedGoogle Scholar
  10. 10.
    Turner AF, Presant CA, Proffitt RT et al. In-in-labeled liposomes: dosimetry and tumor depiction. Radiology 1988; 166 (3): 761–765.PubMedGoogle Scholar
  11. 11.
    Lee JW, Amantea MA, Francis PA et al. Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits. Antimicrobial Agents Chemotherapy 1994; 38 (4): 713–718.CrossRefGoogle Scholar
  12. 12.
    Hiles R, Bekersky I. Pharmacokinetics (PK) of liposomal amphotericin B (AmBisome) in rats. Pharmaceutical Research 1993; 10(1o):S-372 (Abstract #PPDM 8295).Google Scholar
  13. 13.
    Bekersky I, Hiles R. Pharmacokinetics (PK) of liposomal amphotericin B (AmBisome) in dogs. Pharmaceutical Research 1993; io(1o):S-372 (Abstract # PPDM 8296).Google Scholar
  14. 14.
    Walsh TJ, Bekersky I, Yeldandi V et al. Pharmacokinetics of AmBisome in persistently febrile neutropenic patients receiving empirical antifungal therapy. Proceedings of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Abstract A13. 1995: 3.Google Scholar
  15. 15.
    Croft SL, Davidson RNN, Thorton EA. Liposomal amphotericin B in the treatment of visceral leishmaniasis. J Antimicrobial Chemotherapy 1991; 28 (SupplGoogle Scholar
  16. 16.
    Gangneux JP, Sulahian A, Garin Y et al. Therapy of visceral leishmaniasis due to Leishmania infantum: experimental assessment of efficacy of AmBisome. Antimicrobial Agents Chemotherapy 1996; 4o (5): 1214–1218.Google Scholar
  17. 17.
    Van Etten EWM, Van den Heuvel-de Groot C, Bakker-Woudenberg, IAJM. Efficacies of amphotericin B-desoxycholate (Fungizone), liposomal amphotericin B (AmBisome) and Fluconazole in the treatment of systemic candidosis in immunocompetent and leukopenic mice. J Antimicrobial Chemotherapy 1993; 32: 723–739.CrossRefGoogle Scholar
  18. 18.
    Adler-Moore JP, Chiang S, Satorius A et al. Treatment of murine candidosis and cryptococcosis with a unilamellar liposomal amphotericin B formulation (AmBisome). J Antimicrobial Chemotherapy 1991; 28 (Suppl. B): 63–71.CrossRefGoogle Scholar
  19. 19.
    Karyotakis NC, Anaissie, E J. Efficacy of escalating doses of liposomal amphotericin B (AmBisome) against hematogenous Candida lusitaniae and Candida krusei infection in neutropenic mice. Antimicrobial Agents Chemotherapy 1994; 38 (11): 2660–2662.CrossRefGoogle Scholar
  20. 20.
    Francis P, Lee JW, Hoffman A et al. Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits: the potential role of D-mannitol and galactomannan as markers of infection and therapeutic response. J Infectious Diseases 1994; 169: 356–368.CrossRefGoogle Scholar
  21. 21.
    Allen SD, Sorenson KN, Nejdl MJ et al. Prophylactic efficacy of aerosolized liposomal (AmBisome) and non-liposomal (Fungizone) amphotericin B in murine pulmonary aspergillosis. J Antimicrob Chemotherapy 1994; 34: 1001–1013.CrossRefGoogle Scholar
  22. 22.
    Albert MM, Stahl-Carroll TL, Luther MF et al. Comparison of liposomal amphotericin B to amphotericin B for treatment of murine cryptococcal meningitis. J Mycol Med 1995; 5: 1–6.Google Scholar
  23. 23.
    Graybill JR, Boccanegra R. Liposomal amphotericin B therapy of murine histoplasmosis. Antimicrobial Agents Chemotherapy 1995; 39 (8): 1885–1887.CrossRefGoogle Scholar
  24. 24.
    Clemons KV, Stevens DA. Therapeutic efficacy of a liposomal formulation of amphotericin B (AmBisome) against murine blastomycosis. J Antimicrobial Chemotherapy 1993; 32: 465–472.CrossRefGoogle Scholar
  25. 25.
    Clemons KV, Stevens DA. Comparison of a liposomal amphotericin B formulation (AmBisome) and desoxycholate amphotericin B (Fungizone) for the treatment of murine paracoccidioidomycosis. J Med Vet Mycol 1993; 31: 387–394.CrossRefGoogle Scholar
  26. 26.
    Garcia AL. Efficacy of single high dose AmBisome for treatment of murine candidiasis and histoplasmosis. Masters thesis. Pomona CA: California State Polytechnic University, Pomona, 1996;Google Scholar
  27. 27.
    Prentice HG, Catovsky D, Aoun M et al. AmBisome versus amphotericin B in patients with fever unresponsive to antibiotic therapy for 96 h, or with confirmed fungal infection. 2nd International Symposium on Febrile Neutropenia. 1995; Abstract 35.Google Scholar
  28. 28.
    Hann IM, Stevens RF, Pinkerton CR et al. Safety and efficacy of two dose regimes of AmBisome versus amphotericin B as empiric antifungal treatment in neutropenic pediatric patients. n“ Annual Meeting of the European Group for Blood & Bone Marrow Transplantation & 11th Meeting of the Nurses Group, Davos, Switzerland, 1995; Abstract.Google Scholar
  29. 29.
    Ringden O, Meunier F, Tollemar J et al. Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J Antimicrobial Chemotherapy 1991; 28 (suppl B): 73–82.CrossRefGoogle Scholar
  30. 30.
    Tollemar J, Ringden O, Tyden G. Liposomal amphotericin B (AmBisome) treatment in solid organ and bone marrow transplant recipients. Efficacy and Safety Evaluation. Clinical Transplantation 1990; 4: 167–175.Google Scholar
  31. 31.
    Mills W, Chopra R, Linch DC et al. Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single-centre experience of 133 episodes in 116 patients. British Journal Haematology 1994; 86: 754–760.CrossRefGoogle Scholar
  32. 32.
    Schurmann D, De Matos Marques B, Grunewald T et al. Safety and efficacy of liposomal amphotericin B in treating AIDS-associated disseminated cryptococcosis. J Infectious Diseases 1991; 164: 620.Google Scholar
  33. 33.
    Coker RJ, Viviani M, Gazzard BG et al. Treatment of cryptococcosis with liposomal amphotericin B (AmBisome) in 23 patients with AIDS. AIDS 1993; 7: 829–835.PubMedCrossRefGoogle Scholar
  34. 34.
    Leenders ACAP, Reiss P, Portegies P et al. A randomized trial of liposomal amphotericin B (AmBisome) 4 mg/kg versus amphotericin B o.7 mg/kg for cryptococcal meningitis in HIV infected patients. Proceedings of the 36th Interscience Conference on Antimicrobial Agents Chemotherapy. 1996; Abstract LM35.p z87.Google Scholar
  35. 35.
    Viviani MA, Cofrancesco E, Boschetti C et al. Eradication of Fusarium infection in a leukopenic patient treated with liposomal amphotericin B. Mycoses 1991; 34: 255.PubMedCrossRefGoogle Scholar
  36. 36.
    Fisher EW, Toma A, Fisher PH et al. Rhinocerebral mucormycosis: use of liposomal amphotericin B. J Laryngology and Otology 1991; 105: 575.CrossRefGoogle Scholar
  37. 37.
    Seaman J, Boer C, Wilkinson R et al. Liposomal amphotericin B (AmBisome) in the treatment of complicated kala-azar under field conditions. Clin Inf Dis 1995; 21: 188–193.CrossRefGoogle Scholar
  38. 38.
    Emminger W, Graninger W, Emminger-Schmidmeier W et al. Tolerance of high doses of amphotericin B by infusion of a liposomal formulation in children with cancer. Ann Hematol 1994; 6827–31.Google Scholar
  39. 39.
    Zoubek A, Emminger W, Emminger-Schmidmeier W et al. Conventional vs. liposomal amphotericin B in immunosuppressed children. Pediatric Hematology Oncology 1992; 9: 187–190.CrossRefGoogle Scholar
  40. 40.
    Bindschadler DD, Bennett JE. A pharmacologic guide to the clinical use of amphotericin B. J Infectious Diseases 1969; 120(4)427–436.Google Scholar
  41. 41.
    Daneshmend TK, Warnock DW. Clinical pharmacokinetics of systemic antifungal drugs. Clinical Pharmacokinetics 1983; 8: 17–42.PubMedCrossRefGoogle Scholar
  42. 42.
    Anaissie E, Paetznick V, Proffitt R et al. Comparison of the in vitro antifungal activity of free and liposome-encapsulated amphotericin B. Eur J Clin Microbiol Infect Dis 1991; 10: 665–668.PubMedCrossRefGoogle Scholar
  43. 43.
    Garcia AL, Satorius A, Proffitt RT et al. Prophylaxis with single high dose AmBisome (AmBi) minimizes murine histoplasmosis and candidiasis. Abstract, 95`s General Meeting of the American Society for Microbiology, Washington DC 1995: i64.Google Scholar
  44. 44.
    Karyotakis NC, Anaissie EJ, Hachem R et al. Comparison of the efficacy of polyenes and triazoles against hematogenous Candida krusei infection in neutropenic mice. J Infectious Diseases 1993; 168: 1311–1313.CrossRefGoogle Scholar
  45. 45.
    Anaissie EJ, Hachem R, Karyotakis NC et al. Comparative efficacies of amphotericin B, triazoles, and combination of both as experimental therapy for murine trichosporonosis. Antimicrobial Agents Chemotherapy 1994; 38 (11): 2541–2544.CrossRefGoogle Scholar
  46. 46.
    Albert MM, Adams K, Luther MJ et al. Efficacy of AmBisome in murine coccidioidomycosis. J Med Vet Mycol 1994; 32: 467–471.PubMedCrossRefGoogle Scholar
  47. 47.
    Adler-Moore JP. AmBisome targeting to fungal infections. Bone Marrow Transplantation 1994; 14 (Suppl 5): S3 - S7.PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1998

Authors and Affiliations

  • Jill P. Adler-Moore
  • Richard T. Proffitt

There are no affiliations available

Personalised recommendations